Keramari Stergiani, Fidani Liana, Poutoglidis Alexandros, Chatzis Stefanos, Tsetsos Nikolaos, Kaiafa Georgia
Department of Paediatrics, University General Hospital of Thessaloniki AHEPA, Thessaloniki, GRC.
Department of Medical Biology Genetics, Aristotle University of Thessaloniki, Thessaloniki, GRC.
Cureus. 2022 Sep 12;14(9):e29082. doi: 10.7759/cureus.29082. eCollection 2022 Sep.
Adenoviral infections in neonates are associated with high rates of mortality due to the lack of humoral immunity. A comprehensive search of published literature in PubMed, Google Scholar, and Science Direct electronic databases was conducted for case reports published between the years 1990 and 2021. The aim of our study is to investigate the risk factors, clinical manifestations, treatment, and outcomes of adenoviral infections in neonates. In our study, 36 cases were included. The most common type of infection was disseminated one (14/36, 38.8%), followed by adenoviral pneumonia (13/36, 36.1%). Cidofovir was administered in seven cases (19.4%), and death was reported in six of them. One preterm low birthweight neonate with disseminated adenoviral infection was treated with a combination of cidofovir, intravenous immune globulin, and haploidentical virus-specific T lymphocytes (VSTs) and survived. In this review, we found a statistically significant difference in the outcome based on the type of adenoviral infection (p=0.001). Disseminated infection and pneumonia are associated with the worst prognosis. In addition, mortality was observed to be higher in neonates with disseminated disease in contrast to neonates with localized infection (p=0.002). However, the antiviral treatment had no statistically significant effect on the mortality rate (p=0.137). There is a necessity for further investigation and randomized studies to validate the results of the present study.
由于缺乏体液免疫,新生儿腺病毒感染与高死亡率相关。我们对PubMed、谷歌学术和科学Direct电子数据库中发表的文献进行了全面检索,以查找1990年至2021年间发表的病例报告。我们研究的目的是调查新生儿腺病毒感染的危险因素、临床表现、治疗方法及预后。我们的研究纳入了36例病例。最常见的感染类型是播散性感染(14/36,38.8%),其次是腺病毒性肺炎(13/36,36.1%)。7例(19.4%)使用了西多福韦,其中6例死亡。1例患有播散性腺病毒感染的早产低体重新生儿接受了西多福韦、静脉注射免疫球蛋白和单倍体病毒特异性T淋巴细胞(VST)联合治疗并存活。在本综述中,我们发现基于腺病毒感染类型的预后存在统计学显著差异(p=0.001)。播散性感染和肺炎的预后最差。此外,与局限性感染的新生儿相比,播散性疾病的新生儿死亡率更高(p=0.002)。然而,抗病毒治疗对死亡率没有统计学显著影响(p=0.137)。有必要进行进一步的调查和随机研究来验证本研究的结果。